Although, several cancer models including glioblastoma [77], ovarian tumor [78], and melanoma [79] were tested for the anti-tumor efficacy of MSC-TRAIL, studies that show the efficacy of MSC-TRAIL to target cancer stem cells (CSCs) from NSCLC are still insufficiently reported. This evidence concerns the gene TNFSF10 and neoplasm.